ZNF215 Inhibitors
ZNF215 inhibitors encompass a range of chemicals that target various pathways and processes, leading to the functional inhibition of the zinc finger protein ZNF215. Trichostatin A, for instance, inhibits histone deacetylases, which can result in decreased binding of ZNF215 to its DNA targets due to changes in chromatin structure. Similarly, 5-Azacytidine disrupts DNA methylation patterns, potentially altering ZNF215's ability to interact with methylated genomic regions. Proteasome inhibition by MG132 might elevate levels of proteins that hinder ZNF215's function, illustrating another indirect inhibition mechanism. Certain kinase pathway inhibitors, LY294002, and rapamycin, perturb signal transduction routes that either facilitate or restrict ZNF215's interactions or modifications crucial for its role in gene regulation. These alterations could diminish ZNF215's activity by varying the availability or functionality of its co-regulators or by affecting its post-translational modifications.
Furthermore, staurosporine broadly targets protein kinases, possibly affecting ZNF215's phosphorylation state or that of its associated proteins, which is essential for its DNA-binding efficiency. PD98059 and U0126, both MEK inhibitors, disrupt the MAPK/ERK pathway, potentially leading to a protein interaction milieu that is unfavorable for ZNF215's regulatory functions. SP600125, a JNK inhibitor, similarly affects the transcription factor landscape, which can perturb ZNF215's gene regulatory network. Chetomin's disruption of the HIF and p300 interaction could result in the downregulation of genes within ZNF215's regulatory ambit if HIF signaling is involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). By inhibiting HDAC, Trichostatin A increases the acetylation of histones, leading to an open chromatin structure and often transcriptional activation. However, ZNF215 is known to be regulated by chromatin structure, so HDAC inhibition can lead to the reduced binding of ZNF215 to its target DNA sequences. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. It incorporates into DNA and RNA, causing demethylation and inhibiting methylation. By altering the methylation status of DNA, it can change the binding affinity of ZNF215 to methylated DNA sequences, thus indirectly reducing ZNF215's ability to regulate gene expression linked to its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. It prevents the degradation of ubiquitinated proteins, leading to accumulation of these proteins in the cell. ZNF215's activity can be regulated by proteasomal degradation; thus, MG132 may increase the levels of proteins that compete with or inhibit ZNF215, decreasing its functional activity indirectly. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. It blocks the PI3K/AKT signaling pathway, which is crucial for many cellular processes including metabolism, growth, and survival. Inhibition of this pathway can decrease the phosphorylation status of proteins that may be necessary for ZNF215's activity, thereby indirectly reducing its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, rapamycin disrupts downstream signaling pathways that are crucial for cell growth and proliferation. This can lead to a reduced expression of proteins that are essential for ZNF215's function or increase the expression of inhibitors of ZNF215, thereby indirectly inhibiting its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It nonspecifically inhibits a wide range of kinases, which could lead to the inhibition of phosphorylation of ZNF215 itself or of proteins that interact with ZNF215. This lack of phosphorylation can disrupt the function of ZNF215 as it may rely on phosphorylation for its DNA-binding activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which blocks the MAPK/ERK pathway. ZNF215 may function in concert with proteins that are regulated by the ERK pathway. Inhibition of this pathway can lead to changes in the cellular environment that indirectly decrease the functional activity of ZNF215 through altered protein interactions or stability. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, it can alter the activity of transcription factors and cofactors that interact with ZNF215, potentially disrupting the normal function of ZNF215 in gene regulation due to changes in the protein interaction network within the cell. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, which also disrupts the MAPK/ERK pathway. Similar to PD98059, U0126 can lead to a cellular environment that is not conducive to the normal function of ZNF215, due to the altered expression or modification of proteins that regulate or interact with ZNF215, thus indirectly reducing its activity. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the interaction between hypoxia-inducible factor (HIF) and the coactivator p300. By disrupting this interaction, it can reduce the transcriptional activity of HIF target genes. ZNF215 may be involved in gene regulation pathways that are HIF-dependent. Inhibition of HIF activity can therefore decrease the regulatory scope of ZNF215. | ||||||